Navigation Links
Savient Provides Update on Pegloticase BLA
Date:2/12/2009

Company Files Amendments to Strengthen and Clarify BLA Data

FDA Extends PDUFA Action Date to July 30, 2009

Company to Host Conference Call

EAST BRUNSWICK, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Company filed amendments to strengthen and clarify the data included in the previously submitted pegloticase Biologics License Application (BLA), which was granted priority review. The amendments focus on topics identified by the BLA Oversight Committee (the "Committee") of the Board of Directors as a result of its review of the BLA filing and also address review-related questions from the Food and Drug Administration (FDA).

Since its formation on November 19, 2008, the Committee, Chaired by Board Member Dr. Lee S. Simon, M.D., a former Director of the Analgesic, Anti-Inflammatory, Ophthalmologic Drug Products Division of the FDA and a Board Certified Rheumatologist with 25 years of clinical practice experience, has assumed oversight of all Company activities related to the FDA's BLA review process. The Committee has conducted a comprehensive review of the BLA filing with the assistance of external experts. In late January 2009, the Board of Directors also formally retained Dr. Simon as a consultant to assume day-to-day supervision of the BLA and Advisory Panel preparation.

"We believe the steps we have taken further clarify the favorable risk to benefit profile of pegloticase. Securing FDA approval remains our number one priority and we believe making these amendments is an important step toward achieving that goal. We look forward to continuing to work with the FDA as we move through the regulatory process. The Committee, our retained external experts, along with the management team, continue to belie
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. USAID Provides Malaria Assistance to Zimbabwe
3. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. American Dairy Provides Business Update
6. Alfacell Provides ONCONASE(R) NDA Submission Update
7. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
8. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
9. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today that on December 24, ... offering. The Company raised approximately $2.3 ... intends to use the net proceeds from the ...
(Date:12/24/2014)... and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of 2,050,000 shares of its ... 24,949,325 shares of its common stock.  Funds under ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... Kensey Nash Corporation (Nasdaq: KNSY ) ... Exemption (IDE) application to the U.S. Food and Drug ... unique biomaterials technology for treating articular cartilage defects of ... Cartilage Repair Device, which consists of a proprietary bi-phasic, ...
... MAP Pharmaceuticals, Inc. announced today that its initial Phase ... the potential treatment of children with asthma did not ... changes from baseline in nighttime and daytime composite symptom ... with placebo. AstraZeneca (NYSE: AZN ) ...
Cached Medicine Technology:Kensey Nash Announces IDE Submission for Cartilage Repair Device 2Kensey Nash Announces IDE Submission for Cartilage Repair Device 3Kensey Nash Announces IDE Submission for Cartilage Repair Device 4AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints 2
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is ... developing, producing and marketing of a series of induction ... their new series of induction brazing equipments . ... induction brazing refers to the joining of ... and heat. The manager says that there are fundamental ...
(Date:12/25/2014)... December 26, 2014 The report ... to 2023” focuses on the current treatment landscape, ... the colorectal cancer market. Stivarga is a drug ... or rectal cancer. Boehringer Ingelheim is developing nintedanib ... treatment of refractory CRC in the US, Europe, ...
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... sex hormones, testosterone in men and estrogen in women, ... of cartilage tissue. The study suggests hormone replacement in ... beneficial in treating late stages of human osteoarthritis (OA) ... study appear in the April issue of Arthritis ...
... some viral infections fatal and others much less severe ... part of the variability can be attributed to differences ... Katze, presenting at the Society for General Microbiology,s spring ... be a powerful tool to allow treatments to be ...
... this may be why they are less likely to ... (HealthDay News) -- Preconceived attitudes about breast-feeding may explain ... women to breast-feed their infants, a new study shows. ... 2006 were ever breast-fed, compared with 77 percent of ...
... ARBOR, Mich. While radiation therapy is common after ... even among women for whom it would have clear ... from researchers at the University of Michigan Comprehensive Cancer ... for breast cancer, assessing whether they had lumpectomy or ...
... An important gene that normally protects the body against ... on the specific mutation that damages it, according to ... University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and ... mutations in a gene called PTEN. People who inherit ...
... may affect decision-making and self-control , MONDAY, March 29 ... (CRP) are associated with problems in executive thinking skills, ... study. , CRP is considered an indicator of inflammation. ... scans and were given tests of verbal memory, word ...
Cached Medicine News:Health News:Hormone replacement in joint fluid has potential regenerative effect 2Health News:Personalizing medicine to prevent pandemics 2Health News:Black Women in U.S. Comfortable With Formula Feeding 2Health News:Radiation after mastectomy underused, U-M study finds 2Health News:Study shows that mutations in 1 gene cause many cancers 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: